SEC Form 4 · accession 0001209191-17-003660

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 11, 2017

Accepted (ET)

Jan 13, 2017 · 4:12 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jan 11, 2017	M	8,000	$36.30	A	276,225	D
Common Stock^F2,F3	Jan 11, 2017	S	2,400	$81.25	D	273,825	D
Common Stock^F2,F4	Jan 11, 2017	S	2,900	$82.17	D	270,925	D
Common Stock^F2,F5	Jan 11, 2017	S	1,100	$82.92	D	269,825	D
Common Stock^F2,F6	Jan 11, 2017	S	1,100	$84.41	D	268,725	D
Common Stock^F2,F7	Jan 11, 2017	S	500	$84.98	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$36.30	Jan 11, 2017	M	8,000	D	—	Jan 23, 2017	Common Stock	8,000	0	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $81.25 (range $80.61 to $81.60).
F4Open market sales reported on this line occurred at a weighted average price of $82.17 (range $81.62 to $82.55).
F5Open market sales reported on this line occurred at a weighted average price of $82.92 (range $82.64 to $83.24).
F6Open market sales reported on this line occurred at a weighted average price of $84.41 (range $83.72 to $84.70).
F7Open market sales reported on this line occurred at a weighted average price of $84.98 (range $84.87 to $85.11).
F8Fully vested.